Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) (2019)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1093/annonc/mdz061
- Subjects: NEOPLASIAS MAMÁRIAS; METÁSTASE NEOPLÁSICA; RESULTADO DE TRATAMENTO; QUIMIOTERAPIA COMBINADA; ANTINEOPLÁSICOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Annals of oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 30, n. 5, p. 766-773, 2019
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
BACHELOT, T et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology, v. 30, n. 5, p. 766-773, 2019Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdz061. Acesso em: 24 jan. 2026. -
APA
Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., et al. (2019). Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology, 30( 5), 766-773. doi:10.1093/annonc/mdz061 -
NLM
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-shimon S, Wardley A, Merot J-L, Hegg R. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [Internet]. Annals of oncology. 2019 ; 30( 5): 766-773.[citado 2026 jan. 24 ] Available from: https://doi.org/10.1093/annonc/mdz061 -
Vancouver
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-shimon S, Wardley A, Merot J-L, Hegg R. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [Internet]. Annals of oncology. 2019 ; 30( 5): 766-773.[citado 2026 jan. 24 ] Available from: https://doi.org/10.1093/annonc/mdz061 - Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
- Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- Hormonioterapia neoadjuvante no câncer de mama
- Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Tratamento neoadjuvante no câncer de mama
- Terapia estrogenica e cancer de mama
- Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study
Informações sobre o DOI: 10.1093/annonc/mdz061 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
